{
    "clinical_study": {
        "@rank": "96026", 
        "brief_summary": {
            "textblock": "RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients\n      being treated with chemotherapy.\n\n      PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs\n      work in preventing delayed nausea after chemotherapy in patients who have cancer."
        }, 
        "brief_title": "Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer", 
        "completion_date": {
            "#text": "October 2004", 
            "@type": "Actual"
        }, 
        "condition": [
            "Nausea and Vomiting", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Compare the effectiveness of a 5 hydroxytryptamine 3 (5-HT3) receptor antagonist\n           antiemetic vs prochlorperazine in controlling delayed nausea after chemotherapy in\n           patients with chemotherapy-naive cancer.\n\n        -  Compare the effectiveness of prochlorperazine administered on a preventive vs as needed\n           basis in controlling delayed nausea after chemotherapy in these patients.\n\n        -  Compare the quality of life of patients treated with a 5-HT3 receptor antagonist\n           antiemetic vs prochlorperazine.\n\n        -  Compare the quality of life of patients treated with prochlorperazine administered on a\n           preventive vs as needed basis.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to\n      center.\n\n      Patients receive their scheduled chemotherapy regimen containing doxorubicin and their\n      scheduled oral 5 hydroxytryptamine 3 receptor antagonist antiemetic (ondansetron,\n      granisetron, tropisetron, or dolasetron mesylate) combined with dexamethasone on day 1.\n\n      Patients are then randomized to 1 of 3 antiemetic arms.\n\n        -  Arm I: Patients receive oral prochlorperazine every 8 hours on days 2 and 3.\n\n        -  Arm II: Patients receive oral ondansetron every 12 hours, oral granisetron every 12\n           hours, or oral dolasetron mesylate either once a day or every 12 hours on days 2 and 3.\n\n        -  Arm III: Patients receive oral prochlorperazine as needed, up to 4 times per day, on\n           days 2 and 3.\n\n      Quality of life is assessed at baseline and on day 4.\n\n      PROJECTED ACCRUAL: A total of 670 patients will be accrued for this study within 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of cancer for which a chemotherapy regimen containing doxorubicin (with\n             adjuvant, neoadjuvant, curative, or palliative intent) is scheduled\n\n          -  Scheduled chemotherapy regimen must not include any of the following:\n\n               -  Multiple doses of doxorubicin, dacarbazine, hexamethylmelamine, nitrosoureas, or\n                  streptozocin\n\n               -  Doxorubicin HydroCloride liposome or cisplatin\n\n          -  Scheduled chemotherapy regimen may contain agents, other than those listed above,\n             administered orally, IV, or IV continuously on 1 or multiple days\n\n          -  Must be scheduled to receive a 5 hydroxytryptamine 3 (5-HT3) receptor antagonist\n             antiemetic (ondansetron, granisetron, tropisetron, or dolasetron mesylate) with\n             dexamethasone concurrently with doxorubicin\n\n          -  No clinical evidence of an impending bowel obstruction\n\n          -  No symptomatic brain metastasis\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent interferon\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  No prior chemotherapy\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n        Radiotherapy:\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  Concurrent rescue medications (as appropriate) for control of symptoms caused by\n             cancer or its treatment allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00020657", 
            "org_study_id": "CDR0000068694", 
            "secondary_id": [
                "URCC-U3901", 
                "NCI-P01-0180"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "dolasetron mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "granisetron hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "ondansetron", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "prochlorperazine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiemetics", 
                "Prochlorperazine", 
                "Ondansetron", 
                "Granisetron", 
                "Dolasetron mesylate"
            ]
        }, 
        "keyword": [
            "nausea and vomiting", 
            "unspecified adult solid tumor, protocol specific"
        ], 
        "lastchanged_date": "March 4, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/URCC-U3901"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36688"
                    }, 
                    "name": "MBCCOP - Gulf Coast"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85006-2726"
                    }, 
                    "name": "CCOP - Western Regional, Arizona"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259-5404"
                    }, 
                    "name": "CCOP - Mayo Clinic Scottsdale Oncology Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80224"
                    }, 
                    "name": "CCOP - Colorado Cancer Research Program, Incorporated"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96813"
                    }, 
                    "name": "MBCCOP - Hawaii"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62526"
                    }, 
                    "name": "CCOP - Central Illinois"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67214-3882"
                    }, 
                    "name": "CCOP - Wichita"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49007-3731"
                    }, 
                    "name": "CCOP - Kalamazoo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "CCOP - Northern New Jersey"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manhasset", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11030"
                    }, 
                    "name": "CCOP - North Shore University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27104-4241"
                    }, 
                    "name": "CCOP - Southeast Cancer Control Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43206"
                    }, 
                    "name": "CCOP - Columbus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45429"
                    }, 
                    "name": "CCOP - Dayton"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29615"
                    }, 
                    "name": "CCOP - Greenville"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405-0986"
                    }, 
                    "name": "CCOP - Northwest"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment of Delayed Nausea: What Works Best?", 
        "overall_official": {
            "affiliation": "James P. Wilmot Cancer Center", 
            "last_name": "Gary R. Morrow, PhD, MS", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00020657"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Rochester", 
            "investigator_full_name": "Gary Morrow", 
            "investigator_title": "Director, URCC CCOP Research Base", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "results_reference": {
            "PMID": "16198982", 
            "citation": "Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005 Oct;6(10):765-72. Epub 2005 Sep 13."
        }, 
        "source": "University of Rochester", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Gary Morrow", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Allocation: Randomized, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }, 
    "geocoordinates": {
        "CCOP - Central Illinois": "39.84 -88.955", 
        "CCOP - Colorado Cancer Research Program, Incorporated": "39.739 -104.985", 
        "CCOP - Columbus": "39.961 -82.999", 
        "CCOP - Dayton": "39.759 -84.192", 
        "CCOP - Greenville": "34.853 -82.394", 
        "CCOP - Kalamazoo": "42.292 -85.587", 
        "CCOP - Mayo Clinic Scottsdale Oncology Program": "33.494 -111.926", 
        "CCOP - North Shore University Hospital": "40.798 -73.7", 
        "CCOP - Northern New Jersey": "40.886 -74.043", 
        "CCOP - Northwest": "47.253 -122.444", 
        "CCOP - Southeast Cancer Control Consortium": "36.1 -80.244", 
        "CCOP - Western Regional, Arizona": "33.448 -112.074", 
        "CCOP - Wichita": "37.692 -97.337", 
        "MBCCOP - Gulf Coast": "30.694 -88.043", 
        "MBCCOP - Hawaii": "21.307 -157.858"
    }
}